Veracyte (id:6442 VCYT)
40.99 USD
Opening hours: 09:30 - 16:00 (Eastern Standard Time: 12/23/2024 8:12:51 PM)
Exchange closed, opens in 13 hours 17 minutes
About Veracyte
Market Capitalization 3.17B
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Nasal Swab Test for lung cancer diagnosis; and Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis. It is also developing Envisia Classifier, the nCounter analysis system; and LymphMark for lymphoma subtyping test. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
Headquarters (address) |
6000 Shoreline Court South San Francisco 94080 CA United States |
Phone | 650 243 6300 |
Website | https://www.veracyte.com |
Employees | 815 |
Sector | Healthcare |
Industry | Diagnostics & Research |
Ticker | VCYT |
Exchange | NASDAQ Stock Exchange |
Currency | USD |
52 week range | 18.61 - 46.00 |
Market Capitalization | 3.17B |
P/E trailing | -40.09 |
P/E forward | 102.22 |
Price/Sale | 7.45 |
Price/Book | 2.69 |
Beta | 1.67 |
EPS | 3.00 |
EPS United States (ID:6, base:3382) | 24.33 |